@jfais20 · Long OMER · The Analysts

$OMER - reminder for the "drug doesn't work" crowd $AZN (SoC is changing for a reason)

$OMER (L) On Monday, thesis strengthened for Omeros after HSCT-TMA competitor AstraZeneca (AZN) reported that a phase 3 trial failed to achieve statistical significance on the primary endpoint of event-free survival in patients aged 12 or older. AstraZeneca is still moving

Read asLong OMER

Since the call—

unrankedThe analyst's rank today

Medium · 0.88Confidence

Fri, Oct 16Tweeted

Mon, Oct 19 closeCounted from

5% of the basket · day 3fades out by Nov 27

Rank per close

—

Oct 19